Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers
Completed · Phase 1 · Has a placebo group
Conditions studied: Anthrax
In brief
This study will determine the safety and PK of a single IV dose of ETI-204 in subjects 18 to 65 years of age. Three cohorts will be studied with subjects receiving ETI-204. This study will be randomized, double-blind and stratified by gender. Each cohort will contain 36 subjects (including at least four females), 30 who will receive ETI-204 and six who will receive placebo.
Key facts
- Study ID
- NCT01453907
- Run by
- Elusys Therapeutics
- People needed
- 108
- Starts
- 2011-10-01
- Expected to finish
- 2012-12-01
- Last updated by the study team
- 2017-11-14
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Quintiles — Overland Park, Kansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.